ImmunityBio, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG007T9DYW9
IBRX
ImmunityBio, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
ImmunityBio, Inc.
ISIN
US45256X1037
TICKER
IBRX
MIC
XNAS
REUTERS
IBRX.OQ
BLOOMBERG
IBRX US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Wed, 29.01.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, Ltd.), a global oncology company, to conduct a confirmatory randomized Phase 3 clinical trial (ResQ201A-NSCLC), combining BeiGene's tislelizumab, a PD-1 checkpoint inhibitor (CPI), and Immu...
ImmunityBio
Mon, 27.01.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun assessing the marketing authorization application (MAA) for ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-un...
ImmunityBio
Wed, 15.01.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
ImmunityBio
Wed, 15.01.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC).
NMIBC BCG Unresponsive...
ImmunityBio
Mon, 06.01.2025
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code assigned by the Centers for Medicare & Medicaid Services (CMS) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) became effective January 1, 2025. The U.S. Food and Drug Administration...
ImmunityBio
Wed, 11.12.2024
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an aggregate of 33,333,334 shares of its common stock at a price to the public of $3.00 per share. ImmunityBio has granted the underwriters a 30-day option to purchase up to an additional 5,000,...
ImmunityBio
Tue, 10.12.2024
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, ImmunityBio expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of ...
ImmunityBio
Tue, 19.11.2024
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced compelling new data from its ongoing QUILT 3.032 study. As of November 2024, 100 patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS) have been treated with ANKTIVA® (nogapendekin alfa inbaki...
ImmunityBio
Tue, 12.11.2024
ImmunityBio
US45256X1037
ImmunityBio, Inc. (NASDAQ: IBRX) today announced its financial results for the third-quarter ended September 30, 2024.
ANKTIVA® received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025.
ANKTIVA (FDA-approved and commercially available in the U.S. since May 2024) is now widely accessible to patients through commercia...
ImmunityBio
Thu, 24.10.2024
ImmunityBio
US45256X1037
Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin’s lymphoma (NHL). In the QUILT 106 trial, CD19-targeted high-affinity natural killer (t-haNK) cells are bei...
ImmunityBio
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
